Ask about this productRelated genes to: PRKD2 antibody
- Gene:
- PRKD2 NIH gene
- Name:
- protein kinase D2
- Previous symbol:
- -
- Synonyms:
- PKD2, HSPC187, DKFZP586E0820
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2004-10-28
- Date modifiied:
- 2014-11-19
Related products to: PRKD2 antibody
Related articles to: PRKD2 antibody
- Bladder cancer, a widely occurring malignant tumor worldwide, is closely related to the abnormal activation of numerous signaling pathways during its initiation, progression, and metastasis. Protein kinase D2 (PRKD2), as a member of the protein kinase D family, exerts a pivotal influence on human cancers. This research aimed to elucidate the involvement and mechanism of PRKD2 in bladder cancer. - Source: PubMed
Publication date: 2025/11/26
Tian HeSong JingCong JunziZhang ZhihuiDi YanchengYan BenchunNan Xihao - - Source: PubMed
Publication date: 2025/11/26
Zhang GuihuaCao ShengyaGeng ChongSun YueyueXu JingeChen ChongMiao FaanZhang HuanxinKong YunxinJiang RongkeLiu KaigeQi JiaqianLi ZhenyuLiu Hong - Primary sclerosing cholangitis (PSC) is a chronic liver disease strongly linked to inflammatory bowel disease (IBD), yet its causal genetic drivers and the mechanisms underlying this comorbidity remain poorly understood. This study aimed to identify causal genes for PSC and elucidate the role of the gut-liver axis in its pathogenesis. - Source: PubMed
Publication date: 2025/11/04
Chen YuZhang Hui-HongLu Yu-XuanLao LinLiao ShanyingLi JieDai Shi-Xue - Multiple myeloma (MM) remains incurable, as most patients relapse or become refractory (RRMM), and the molecular nexus among clonal evolution, immune escape and therapy response remains unknown. Bulk RNA-seq from 24 MM to 6 matched marrows (subset of 132) plus single-cell datasets were analysed by differential expression, pseudotime, WGCNA, enrichment, immune deconvolution and GDSC drug screens. PRKD2 was knocked down (KD) or over-expressed (OE) in H929, 8226 and U266 cells. Viability (CCK-8) and apoptosis (Annexin V/7-AAD) were assessed after 48 h of axitinib (1.25-10 µM). PRKD2 was the sole gene uniformly up-regulated in newly diagnosed MM, RRMM and poor-survival cohorts, rising along the malignant plasma-cell trajectory. High PRKD2 aligned with ISS-III stage, elevated mRNAsi/EREG_mRNAsi and worse 5-year survival (38% vs. 73%, P = 0.012). PRKD2-KD reduced proliferation (~ 30%) and restored HLA-E, whereas PRKD2-OE suppressed antigen-presentation genes and polarised macrophages toward an IL-6/MERTK tumour-promoting phenotype. PRKD2-high marrow contained more naïve/memory B cells but fewer mature plasma cells. PRKD2 expression correlated positively with axitinib sensitivity (- log IC, r = 0.68; P < 0.001). Experimentally, PRKD2-OE cells showed a 1.4-fold increase in axitinib-induced apoptosis, while PRKD2-KD cells were intrinsically pro-apoptotic and further sensitised; axitinib abolished the growth advantage conferred by PRKD2-OE. PRKD2 integrates secretory stress, stem-like programmes and immune evasion, driving aggressive MM yet exposing a vulnerability to VEGFR/PDGFR blockade. Direct PRKD2 targeting or axitinib-based combinations-including proteasome inhibition-deserve clinical evaluation for high-risk MM. - Source: PubMed
Publication date: 2025/10/21
Zhang GuihuaCao ShengyaGeng ChongSun YueyueXu JingeChen ChongMiao FaanZhang HuanxinKong YunxinJiang RongkeLiu KaigeQi JiaqianLi ZhenyuLiu Hong - Protein kinase D (PKD) is a family of serine/threonine kinases encoded by three genes-Prkd1, Prkd2, and Prkd3. PKD has been implicated in regulating cell proliferation, apoptosis, motility, and protein trafficking, but its physiological roles during embryonic development remain incompletely understood. In this study, we aimed to investigate the effects of PKD deletion on embryonic survival and development in mice. - Source: PubMed
Publication date: 2025/10/13
Huang LeiCai ShangbinWang HongZhu XiangbinLi NaWang ShijiaCheng HongqiangChen JuOuyang Kunfu